De Re V, Boiocchi M, De Vita S, Dolcetti R, Gloghini A, Uccini S, Baroni C, Scarpa A, Cattoretti G, Carbone A
Division of Experimental Oncology 1, Centro di Riferimento Oncologico, Aviano, Italy.
Int J Cancer. 1993 Jul 30;54(6):895-8. doi: 10.1002/ijc.2910540603.
Epstein-Barr virus (EBV) type 2 is considered to be a much less potent transformer of lymphocytes than type 1. However, type-2 EBV may be involved in the pathogenesis of non-Hodgkin's lymphomas (NHLs) arising in immunocompromised patients, i.e., subjects with malaria or HIV-1 infection. To determine whether type-2 EBV may also play a role in Hodgkin's disease (HD) developing in immunocompromised patients, we characterized EBV subtypes in EBV-positive HD samples from 10 HIV-1-positive patients as well as from a control population of 24 HIV-1-negative patients. Type-2 EBV was detected in 5/10 HD samples from the HIV-1-positive group (1 case showed concomitant type-1 EBV positivity), but only in 1/20 HD samples from the HIV-1-negative group, indicating that, during HIV-1-induced immunodepression, type-2 EBV may be pathogenetically involved also in HD, as previously reported for HIV-associated NHLs.
2型爱泼斯坦-巴尔病毒（EBV）被认为在淋巴细胞转化方面的能力远低于1型。然而，2型EBV可能参与免疫功能低下患者（即患有疟疾或HIV-1感染的个体）中非霍奇金淋巴瘤（NHL）的发病机制。为了确定2型EBV是否也可能在免疫功能低下患者发生的霍奇金病（HD）中起作用，我们对10例HIV-1阳性患者以及24例HIV-1阴性对照人群的EBV阳性HD样本中的EBV亚型进行了特征分析。在HIV-1阳性组的10份HD样本中有5份检测到2型EBV（1例同时显示1型EBV阳性），但在HIV-1阴性组的20份HD样本中仅1份检测到，这表明在HIV-1诱导的免疫抑制过程中，2型EBV可能也在HD的发病机制中起作用，正如先前关于HIV相关NHL的报道。
